As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Edgewise Therapeutics Inc. The largest reported stake is Paradigm BioCapital Advisors LP's, at 9.5%. 14 filings are on record since July 17, 2025 (Schedule 13G/A, August 14, 2026).
Who owns Edgewise Therapeutics, Inc.?
Sell to companies like Edgewise Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fmr LLC · Sole voting: 970,341 · Shared voting: 0 · Sole dispositive: 970,920 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-05
- · Reporting person: Paradigm BioCapital Advisors LP · Sole voting: 10,215,455 · Shared voting: 0 · Sole dispositive: 10,215,455 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 8,392,730 · Sole dispositive: 0 · Shared dispositive: 8,392,730 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Baker Bros. Advisors LP · Sole voting: 3,701,719 · Shared voting: 0 · Sole dispositive: 3,701,719 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Fmr LLC · Percent: 5.1% · SCHEDULE 13G
Edgewise Therapeutics Inc has 14 Schedule 13D or 13G filings on record since 2025-07-17. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Paradigm BioCapital Advisors LP | 9.5% | 10,215,455 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| RA Capital Management, L.P. | 7.8% | 8,392,730 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| BlackRock, Inc. | 5.5% | 5,824,866 | SCHEDULE 13G/A, 2025-07-17 | 2025-06-30 |
| Janus Henderson Group Plc | 5.5% | 5,915,556 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| Novo Holdings A/S | 4.9% | 5,350,000 | SCHEDULE 13D/A, 2026-04-27 | 2026-04-23 |
| Perceptive Advisors LLC | 4.4% | 4,639,949 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Baker Bros. Advisors LP | 3.4% | 3,701,719 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Fmr LLC | 0.9% | 970,920 | SCHEDULE 13G/A, 2026-11-05 | 2026-09-30 |
Holding shares or following this stake? See who's behind Edgewise Therapeutics Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Edgewise Therapeutics Inc and the records around it.
Edgewise Therapeutics Inc elsewhere on the record
Companies that share a holder
- Novo Holdings A/S also filed stake reports on 11 other companies: Avalyn Pharma Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026), Obsidian Therapeutics, Inc. (Aug 2026)
- Paradigm BioCapital Advisors LP also filed stake reports on 22 other companies: Obsidian Therapeutics, Inc. (Oct 2026), Spyre Therapeutics, Inc. (Oct 2026), Tyra Biosciences, Inc. (Sep 2026)
- Baker Bros. Advisors LP also filed stake reports on 25 other companies: Madrigal Pharmaceuticals, Inc. (Nov 2026), Kodiak Sciences Inc. (Sep 2026), BeOne Medicines Ltd. (Sep 2026)
Watch Edgewise Therapeutics Inc
Get an email when Edgewise Therapeutics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Edgewise Therapeutics Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Edgewise Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Edgewise Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Paradigm BioCapital Advisors LP | 10,215,455 | 0 | 10,215,455 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Paradigm BioCapital Advisors GP LLC | 10,215,455 | 0 | 10,215,455 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Senai Asefaw, M.D. | 10,215,455 | 0 | 10,215,455 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Paradigm BioCapital International Fund Ltd. | 8,961,631 | 0 | 8,961,631 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| RA Capital Management, L.P. | 0 | 8,392,730 | 0 | 8,392,730 | SCHEDULE 13G/A, 2026-08-14 |
| Peter Kolchinsky | 0 | 8,392,730 | 0 | 8,392,730 | SCHEDULE 13G/A, 2026-08-14 |
| Rajeev Shah | 0 | 8,392,730 | 0 | 8,392,730 | SCHEDULE 13G/A, 2026-08-14 |
| RA Capital Healthcare Fund, L.P. | 0 | 8,392,730 | 0 | 8,392,730 | SCHEDULE 13G/A, 2026-08-14 |
| Baker Bros. Advisors LP | 3,701,719 | 0 | 3,701,719 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Baker Bros. Advisors (GP) LLC | 3,701,719 | 0 | 3,701,719 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Julian C. Baker | 3,701,719 | 0 | 3,701,719 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Felix J. Baker | 3,701,719 | 0 | 3,701,719 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Fmr LLC | 970,341 | 0 | 970,920 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Abigail P. Johnson | 0 | 0 | 970,920 | 0 | SCHEDULE 13G/A, 2026-11-05 |
The latest filing identifies Edgewise Therapeutics Inc by CUSIP 28036F105 and gives its principal executive office as 1715 38TH ST, BOULDER, CO 80301 (SCHEDULE 13G/A, 2026-11-05).
What the percentages are based on
See Item 11 on the cover page for each Reporting Person. The percentages of beneficial ownership contained herein are based on 107,593,006 shares of Common Stock outstanding as of April 30, 2026, as reported by the Issuer in its Form 10-Q filed with the SEC on May 7, 2026.Paradigm BioCapital Advisors LP, SCHEDULE 13G/A, 2026-08-14
Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentages of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.RA Capital Management, L.P., SCHEDULE 13G/A, 2026-08-14
The information in Item 11 of each of the cover pages to this Schedule 13G is incorporated herein by reference. The percentage of beneficial ownership for each of the Reporting Persons reported herein is based on 107,776,380 shares of Common Stock outstanding as of June 30, 2026, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 6, 2026.Baker Bros. Advisors LP, SCHEDULE 13G/A, 2026-08-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-17 | BlackRock, Inc. | 5.5% | SCHEDULE 13G/A |
| 2025-08-14 | Perceptive Advisors LLC | 4.4% | SCHEDULE 13G/A |
| 2025-08-14 | Baker Bros. Advisors LP | 6.9% | SCHEDULE 13G/A |
| 2025-08-14 | Janus Henderson Group Plc | 5.2% | SCHEDULE 13G/A |
| 2025-11-14 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G/A |
| 2025-11-14 | Janus Henderson Group Plc | 4.7% | SCHEDULE 13G/A |
| 2026-02-17 | Paradigm BioCapital Advisors LP | 6.2% | SCHEDULE 13G/A |
| 2026-04-27 | Novo Holdings A/S | 4.9% | SCHEDULE 13D/A |
| 2026-05-15 | Janus Henderson Group Plc | 5.5% | SCHEDULE 13G |
| 2026-08-06 | Fmr LLC | 5.1% | SCHEDULE 13G |
| 2026-08-14 | Baker Bros. Advisors LP | 3.4% | SCHEDULE 13G/A |
| 2026-08-14 | Paradigm BioCapital Advisors LP | 9.5% | SCHEDULE 13G/A |
| 2026-08-14 | RA Capital Management, L.P. | 7.8% | SCHEDULE 13G/A |
| 2026-11-05 | Fmr LLC | 0.9% | SCHEDULE 13G/A |
Questions about who owns Edgewise Therapeutics Inc
Who owns Edgewise Therapeutics Inc?
On this page, 4 holders' latest ownership filings report 5% or more of Edgewise Therapeutics Inc: Paradigm BioCapital Advisors LP (9.5%, Schedule 13G/A, filed 2026-08-14), RA Capital Management, L.P. (7.8%, Schedule 13G/A, filed 2026-08-14), BlackRock, Inc. (5.5%, Schedule 13G/A, filed 2025-07-17) and Janus Henderson Group Plc (5.5%, Schedule 13G, filed 2026-05-15).
Who are the largest shareholders of Edgewise Therapeutics Inc?
By the share each holder's latest filing reports, the largest holders of Edgewise Therapeutics Inc on this page are Paradigm BioCapital Advisors LP (9.5%), RA Capital Management, L.P. (7.8%) and BlackRock, Inc. (5.5%).
When did Paradigm BioCapital Advisors LP buy into Edgewise Therapeutics Inc?
The filings give report dates, not purchase dates. The earliest filing from Paradigm BioCapital Advisors LP on this page is the Schedule 13G/A, filed 2026-02-17, reporting 6.2%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 14 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Edgewise Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.